<SEC-DOCUMENT>0001193125-23-085824.txt : 20230331
<SEC-HEADER>0001193125-23-085824.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230330174526
ACCESSION NUMBER:		0001193125-23-085824
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230330
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23782019

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d490541d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated March 30, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d490541dex991.htm"><B>Immutep Announces Expansion of Triple Combination Therapy in 1</B><B>st </B><B>Line Non-Small Cell Lung Cancer</B>
</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March 30, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d490541dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:14%; text-indent:0%">


<IMG SRC="g490541g0330084353592.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Expansion of Triple Combination Therapy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expanding <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial evaluating efti with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy to 50 patients
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expansion based on safety and strong initial efficacy results </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data updates expected throughout CY2023 and cost-efficient approach through investigator-initiated trial will
further inform options related to 1L NSCLC development </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both
chemo-free <FONT STYLE="white-space:nowrap">IO-IO</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> triple combinations </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 30</B><B></B><B>&nbsp;March 2023 &#150; </B><U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the <FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> trial evaluating the combination of eftilagimod alpha (&#147;efti&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC class II agonist, in conjunction with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy in 1st line <FONT STYLE="white-space:nowrap">non-</FONT> small cell lung cancer (1L NSCLC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> recently reached its initial enrolment target of 20 patients and will now be expanded to 50 patients
across multiple sites. This expansion is based on favourable safety and strong initial efficacy results presented at SITC 2022. Additional data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is expected throughout calendar year 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prof. Dr.&nbsp;Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF and lead investigator noted: &#147;We&#146;re thrilled to expand the
trial population for this triple combination therapy, which has demonstrated promising efficacy and safety in 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients. We have seen the previous findings that are
indicative of powerful synergies of efti&#146;s immune system stimulation with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapies and separately with chemotherapy across various solid tumors. As we
continue to gather clinical data throughout the year, we eagerly anticipate discovering how this synergy translates in the <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> study, which combines all three modalities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial results from the triple combination of efti, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and
chemotherapy in patients with 1L NSCLC show that the therapy is well-tolerated and provides promising early signals of therapeutic activity with an ORR of 72.7% and a Disease Control Rate (DCR) of 90.9%. Additionally, 82% of the eleven evaluable
patients had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) of &lt;50% and this group reported an encouraging 66.7% ORR and 88.9% DCR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with low to negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression represent <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the 1L
NSCLC patient population and are less responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapy compared to patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS of &#8805;50%.
Unlike many dual immuno-oncology combinations <FONT STYLE="white-space:nowrap">(IO-IO)</FONT> that focus solely on high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients, compelling clinical results to date suggest that efti may be
uniquely positioned to address the entire NSCLC patient population regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression through chemo-free <FONT STYLE="white-space:nowrap">IO-IO</FONT> combinations or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> triple combinations as <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is evaluating. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g490541g0330084353592.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Company&#146;s late-stage clinical development efforts focused on 1L NSCLC with the
combination of efti and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy <FONT STYLE="white-space:nowrap">(IO-IO),</FONT> the expansion of <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> will
further inform planning for registrational studies. Importantly, this multi-center investigator-initiated trial will generate valuable data in a cost-efficient manner. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, said: &#147;We are grateful for the long-standing support of Dr.&nbsp;Al-Batran and the entire team at IKF. Our valuable relationship
with this world-class institution has uncovered many positive attributes of efti and continues to help us cost-effectively advance this novel immunotherapy for patients with advanced solid tumours, including 1st line
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INSIGHT-003 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF. It is being
run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple combination therapy in front line
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients consisting of efti administered subcutaneously in conjunction with an existing approved
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy (pembrolizumab) and chemotherapy
(carboplatin and pemetrexed) delivered intravenously. The trial will assess the safety, tolerability, and initial efficacy of the combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer. Efti is an agonist to
major-histocompatibility index (MHC) Class&nbsp;II on antigen presenting cells (APCs) that binds to and uniquely activates these APCs via MHC II leading to activation/proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells,
NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to
fight cancer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g490541g0330084353592.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris
Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g490541g0330084353592.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g490541g0330084353592.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I S # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX=Z--/J3:O*K"&)66-F'WW/4CZ#/YUZ=0 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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H^EW^9_QJ:STG64OK=GM;H(LJ%B2< 9&>]>DTAZT>R7<%A8IWNS__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
